Novel vaccine delivery systems: solutions to HIV vaccine dilemmas?
Sutter
G
G
GSF-Institut für Molekulare Virologie, Institut für Virologie, TU München, Trogerstrasse 4b, 81675 München, Germany. sutter@gsf.de
Haas
J
J
D016915:AIDS Vaccines / Q000008:administration & dosage* / Q000235:genetics / Q000276:immunology; D000276:Adjuvants, Immunologic; D000818:Animals; D005822:Genetic Vectors; D015658:HIV Infections / Q000517:prevention & control; D015497:HIV-1 / Q000235:genetics / Q000276:immunology; D006801:Humans; D014611:Vaccination; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000276:immunology; D017778:Vaccines, Combined / Q000008:administration & dosage / Q000276:immunology; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000276:immunology; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology
D016915:AIDS Vaccines; D000276:Adjuvants, Immunologic; D014613:Vaccines, Attenuated; D017778:Vaccines, Combined; D019444:Vaccines, DNA; D014614:Vaccines, Synthetic